Sanofi recently announced an expansion of its licensing agreement with Novavax, granting it broader rights to use Novavax's Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program ...
Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® ...
GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has signed a three-year agreement ...
Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding ...
(RTTNews) - Biopharmaceutical company Novavax, Inc. (NVAX), which advances protein-based vaccines with its novel Matrix-M adjuvant, announced on Monday that it has signed a three-year agreement with ...
Novavax (NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), in the European ...
SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologic s, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback